One dirt-cheap FTSE 100 stock I’d buy today and one I’d sell

Royston Wild looks at two FTSE 100 (INDEXFTSE: UKX) shares with very different investment outlooks.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shire (LSE: SHP) was back on the march in Tuesday trading as speculation over a possible takeover by Japan’s Takeda Pharmaceutical Company heated up.

The FTSE 100 pharma play, which was 6% higher from Monday’s close at pixel time, has so far resisted the overtures of its Asian peer. How far Takeda will chase Shire’s share price higher remains to be seen, but given the determination it has shown so far — allied with Shire’s still cheap valuation — this story could well have much more distance to run.

It isn’t difficult to see why it is such a peach in Takeda’s eyes. The British company is a giant in the growing field of rare diseases, and its fast-improving pipeline provides plenty of revenues opportunities in the years ahead. Indeed, the number of programmes in its pipeline doubled in the four years to 2017 and now stands at around 40. What’s more, the sale of the oncology division to Servier for $2.4bn this month provides it with greater resources to dedicate to keep developing its core operations.

Shire is expected to report earnings growth of 7% in both 2018 and 2019, forecasts that leave it dealing on a dirt-cheap forward P/E multiple of 11.2 times. I reckon this is a bargain given that its strong pipeline could well deliver titanic profits growth later down the line.

Shop around

I am a lot less confident over fellow Footsie member Next’s (LSE: NXT) ability to generate strong earnings progression in the years ahead.

I myself used to own shares in the clothing giant, drawn in by the large dividend yields on offer. But I sold out several years ago as soon as the intense competitive pressures became apparent, putting stress on the retailer’s sales-driving Next Directory online and catalogue division.

These strains have become even more apparent as Next’s rivals have invested heavily in their own e-commerce operations in an effort to stay relevant in our increasingly-digitalised world. And since I held my shares, conditions on the high street have become that much more difficult as shopper budgets have become more and more constrained.

Against this backcloth, Next has seen earnings dip for the past two consecutive years, putting paid to its esteemed growth record.

And while a marginal earnings bounceback is forecast for the year to January 2019, leading to a predicted 4% rise in fiscal 2020, I am not convinced. As a consequence a low forward P/E ratio of 12.5 times fails to attract me.

In fact, I would consider a reading below the bargain watermark of 10 times to be a fairer reflection of sustained profits gloom as consumers continue to tighten their pursestrings. Chairman Michael Roney commented last month that “the wider economy, clothing market and high street look set to remain challenging.”

And with Next also battling against a rising cost base, I reckon the company is far too risky right now, and wouldn’t be surprised to see current forecasts heavily downgraded in the months ahead.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended Shire. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »